Financial Performance - The company achieved total operating revenue of CNY 153,986,329.89, representing a year-on-year increase of 12.24%[5] - Net profit attributable to shareholders decreased by 58.84% to CNY 16,472,240.03, with basic earnings per share at CNY 0.10, down 60% from the previous year[4] - Total assets at the end of the reporting period were CNY 253,350,091.77, a decrease of 8.63% compared to the beginning of the period[5] - The equity attributable to shareholders decreased by 11.93% to CNY 231,897,324.76[5] Market Conditions - The domestic pig price dropped by 48% from its peak in October 2022, significantly impacting the company's business[6] - The total production of feed additives in the country was 14,688,000 tons, a decline of 0.6% year-on-year, with mixed feed additives down 8.8%[6] Product Development and Strategy - The company launched a series of new products aimed at cost reduction and efficiency improvement for downstream industries, currently in the market expansion and user cultivation phase[6] - The company plans to accelerate the nationwide market layout and new customer development for animal blood products, focusing on high-quality development policies[7] - The company aims to enhance its research and development efforts in the animal blood nutrition sector to create better performance for shareholders[7] Risk Awareness - The company emphasizes the importance of risk awareness as the financial data is preliminary and subject to final audit[8]

Financial Performance - The estimated net profit attributable to shareholders for 2022 is projected to be between 16 million to 20 million CNY, representing a decrease of 50% to 60% compared to the previous year's profit of 40.017 million CNY[4]. Market Challenges - The decline in performance is primarily attributed to the impact of strict pandemic controls, which hindered customer visits and experiments, as well as significant disruptions in sales channels and logistics[5]. - The domestic livestock and poultry breeding market has faced ongoing challenges due to macroeconomic downturns, leading to weakened consumer demand and rising costs[6]. Product Development - New products launched in 2022 are currently in the market expansion and user cultivation phase, resulting in lower gross margins compared to older products[6]. - The company plans to accelerate nationwide market layout and new customer development, focusing on enhancing product research and development in the animal hematopoietic nutrition sector[6].

Financial Performance - Operating revenue for the first nine months of 2022 was approximately CNY 106.03 million, an increase of 8.68% year-on-year[15]. - Net profit attributable to shareholders decreased by 52.47% to approximately CNY 14.58 million[15]. - Basic earnings per share for the first nine months of 2022 were CNY 0.09, down 60.87% from the previous year[15]. - Revenue for Q3 2022 was approximately CNY 41.80 million, a 9.78% increase compared to Q3 2021[15]. - Net profit for Q3 2022 was approximately CNY 8.43 million, a decrease of 17.90% year-on-year[15]. - The net profit attributable to shareholders for the first nine months of 2022 was CNY 14.58 million, a decrease of 52.47% year-on-year, while the net profit after deducting non-recurring items was CNY 8.14 million, down 69.22%[18]. - The total profit for Q3 2022 was CNY 9,143,257.18, a decline of 24.5% compared to CNY 12,074,394.59 in Q3 2021[49]. - The company's gross profit margin for Q3 2022 was approximately 56.9%, compared to 62.3% in Q3 2021[52]. - The company's retained earnings decreased to ¥31,003,398.28 from ¥34,198,819.23, a decline of about 9.3%[45]. Assets and Liabilities - Total assets as of September 30, 2022, were approximately CNY 262.94 million, a decrease of 5.43% compared to the end of the previous year[15]. - The company reported a debt-to-asset ratio of 7.68% on a consolidated basis, up from 5.04% at the end of the previous year[15]. - The company's total assets as of September 30, 2022, amounted to CNY 262.23 million, a decrease of 5.43% year-on-year, primarily due to a reduction in cash and receivables[17]. - The total liabilities increased to CNY 19,937,426.00 from CNY 13,576,301.94, marking an increase of approximately 47.5%[40]. - The total assets of Guangdong Drive Biological Technology Group as of September 30, 2022, amounted to CNY 262,940,945.83, a decrease from CNY 277,276,529.02 at the end of 2021[38]. - The company's cash and cash equivalents were CNY 10,859,972.12, down from CNY 32,399,560.97 at the end of 2021, indicating a significant liquidity reduction[38]. - The accounts receivable decreased to CNY 33,044,155.03 from CNY 39,036,068.40, reflecting a decline of approximately 15.4%[38]. - The company's inventory decreased to ¥7,955,963.12 from ¥9,298,984.81, reflecting a reduction of about 14.4%[44]. Cash Flow - Cash flow from operating activities increased significantly by 7,762.57% to approximately CNY 36.52 million[15]. - The net cash flow from operating activities for the first nine months of 2022 was CNY 36,517,064.14, compared to CNY 464,441.59 in the same period of 2021, indicating a substantial improvement[56]. - Cash inflow from operating activities for the first nine months of 2022 was CNY 132,651,880.32, a significant increase from CNY 88,685,470.29 in the same period of 2021, marking a growth of approximately 49.6%[56]. - Cash outflow from investing activities for the first nine months of 2022 totaled CNY 261,578,579.41, compared to CNY 249,128,553.60 in 2021, reflecting an increase of about 5%[56]. - The net cash flow from investing activities for the first nine months of 2022 was -CNY 22,077,489.40, an improvement from -CNY 35,848,541.90 in the same period of 2021[56]. - Cash inflow from financing activities amounted to 56,226,400.00, with no new borrowings or bond issuances reported[60]. - Cash outflow for financing activities was 35,599,626.59, up from 20,786,002.39 in the previous period[60]. - The net increase in cash and cash equivalents was -21,072,265.77, compared to a slight increase of 378,653.20 previously[60]. Dividends and Shareholder Information - The company distributed cash dividends of CNY 34.11 million during the reporting period, impacting retained earnings[17]. - The proposed dividend distribution for the third quarter is CNY 0.80 per 10 shares, with no stock bonus or capital increase planned[35]. - The total number of ordinary shares at the end of the reporting period was 160,277,600 shares, with 5,054 shareholders[24]. - The stock option plan for 2022 involved granting 1,887,914 options to 32 individuals, with an exercise price set at CNY 4.61 per option[36]. Research and Development - The company is focused on developing new products and technologies in the feed additive sector to enhance nutritional value and improve animal health[6]. - The company is focusing on market expansion through the introduction of new products aimed at cost reduction and efficiency improvement for downstream industries[18]. - Research and development expenses for Q3 2022 were CNY 907,325.24, slightly down from CNY 948,143.14 in Q3 2021[52]. Other Financial Metrics - Non-recurring gains and losses totaled CNY 7.55 million for the reporting period, with a net amount of CNY 6.44 million after tax[21]. - The company’s weighted average return on equity was 3.47% for the reporting period, down from 4.04% in the previous year[19]. - The company incurred a credit impairment loss of CNY 1,553,916.12 in Q3 2022, compared to a loss of CNY 431,120.48 in Q3 2021[49]. - The company reported a significant increase in other income to ¥37,665.00 in Q3 2022 from ¥520,000.00 in Q3 2021, indicating a change in revenue sources[48]. - Basic and diluted earnings per share for Q3 2022 were both CNY 0.16, up from CNY 0.05 in Q3 2021, representing a 220% increase[53].

Product Development and Innovation - The company launched a new product "Xuexue Wang" which received the "Yue Brand" certification[4] - The company has obtained 1 new invention patent for a method of preparing L-Alany-L-Glutamine[4] - The company obtained a new invention patent for a method of preparing L-phenylalanine-L-glutamine, enhancing its R&D capabilities[34] - The company established the Animal Health Digital Research Institute and launched a new product on January 8, 2022[5] - The company is actively developing blood and related derivative products to improve animal health and disease resistance[14] - The company focuses on health blood products, including "Xie Xue Su," "Xie Xue Wang," and "Xie Xue Le," which are designed to enhance animal health and performance[22] - The company has established a blood nutrition R&D center to improve animal health and disease resistance[87] Market Expansion and Strategy - The company is focusing on expanding its product range to cover aquaculture and ruminants, aiming to reduce reliance on a single animal sector[13] - The company aims to expand its market presence by increasing awareness of blood nutrition among aquaculture farmers[16] - The company plans to expand its product range to include aquatic and ruminant animal markets to mitigate risks from single species epidemics[86] - The company launched new products aimed at cost reduction and efficiency improvement for the downstream industry, which are currently in the market expansion and user cultivation phase[38] Financial Performance - The company reported a revenue of CNY 64,232,221.91, an increase of 7.98% compared to the same period last year[28] - The net profit attributable to shareholders decreased by 69.87% to CNY 6,147,419.47, down from CNY 20,401,064.78 in the previous year[28] - The gross profit margin dropped significantly to 20.35% from 50.78% year-on-year[28] - Total assets decreased by 10.22% to CNY 248,944,043.71 compared to the end of the previous year[29] - The company achieved a net cash flow from operating activities of CNY 27,011,084.65, a substantial increase of 342.72% year-on-year[30] - The company’s weighted average return on equity decreased to 2.36% from 8.38% year-on-year[28] - The company’s total liabilities increased by 4.61% to CNY 14,621,331.51 compared to the previous year[29] Shareholder and Ownership Structure - The actual controller holds a total of 57.5153% of the company's shares, with Liu Jinping and Liu Pingxiang directly holding 33.2348% and 21.9104% respectively[14] - The total share capital of the company is 160,277,600 shares[23] - The company reported a total shareholding of 124,376,786 shares, representing 77.60% of the total shares outstanding[127] - Major shareholders include Liu Jinping with 54,868,015 shares (34.23%) and Liu Pingxiang with 35,117,429 shares (21.91%)[127] Risks and Challenges - The company is facing risks from market competition due to counterfeit products that may affect its brand image[13] - The company has not experienced any significant changes in major risks during the reporting period[14] - The company has not identified any delisting risks[14] Corporate Governance and Compliance - The company has ensured compliance with legal regulations regarding information disclosure, maintaining accuracy and completeness[98] - The actual controller has committed to not occupying company funds and avoiding any related party transactions outside of normal business operations[102] - The company has committed to ensuring that any economic losses arising from the rental of factory premises will be fully compensated by the actual controlling shareholders[103] Employee and Community Engagement - The company added 23 new employees, contributing to local employment stability[83] - The company donated living supplies to the COVID-19 prevention command in Guangzhou Baiyun District in 2022[83] - The total number of employees increased from 74 to 76, with a net addition of 24 employees during the reporting period[152] Research and Development - The company is enhancing its R&D capabilities by collaborating with well-known universities and research institutes[13] - Research and development expenses rose by 9.87% to $2,293,360.29, reflecting the company's focus on developing new products[61][63] Stock and Financing Activities - The company initiated a stock option incentive plan for 2022[4] - The company repurchased 900,000 shares, accounting for 0.56% of the total share capital, with a total payment of approximately ¥6.06 million[96] - The company has committed to avoiding any form of competition with its actual controller, ensuring no similar business activities are undertaken[99] Economic Contributions - The company contributed approximately RMB 600,000 in taxes to national and local governments during the reporting period[83]

Group 1: Research and Development - The company has a good cash flow and is continuously increasing R&D investment, having launched multiple specialized research projects this year [3] - In 2022, the company added 1 new invention patent and launched several new products, including Xuexue Milk (for ruminants) and organic aloe [4] - The company has developed products that effectively degrade mold in feed materials and enhance blood oxygen levels, improving feed utilization and reducing health costs [4] Group 2: Market Expansion and Product Applications - The company is expanding its applications in the ruminant field and is actively planning to enter the aquaculture sector [3] - The main business focus is on developing, producing, and selling feed additives that enhance animal blood production capabilities [4] - The company has achieved significant results in improving non-specific immunity against seasonal swine fever and has made breakthroughs in treating blue ear disease through blood production technology [4] Group 3: Capital Market Plans - Since its listing on the Beijing Stock Exchange, the company is learning relevant regulations and will consider stock issuance or convertible bonds for acquisitions if suitable targets arise [3]

Financial Performance - The net profit attributable to shareholders for Q1 2022 was approximately ¥2.07 million, representing a significant decline of 76.68% year-over-year[16]. - The operating revenue for Q1 2022 was approximately ¥28.57 million, down 9.86% from ¥31.69 million in Q1 2021[16]. - The basic earnings per share for Q1 2022 was ¥0.01, down 87.50% from ¥0.08 in the same period last year[16]. - The weighted average return on equity based on net profit attributable to shareholders was 0.78% for Q1 2022, down from 3.84% in Q1 2021[16]. - The decline in net profit was primarily due to a decrease in sales caused by COVID-19 pandemic restrictions, resulting in a revenue drop of approximately ¥3.12 million[18]. - Total operating revenue for Q1 2022 was CNY 28,568,911.26, a decrease from CNY 31,692,702.57 in Q1 2021, representing a decline of approximately 6.7%[67]. - Net profit for the first quarter of 2022 was 2,072,317.04 yuan, down from 8,884,754.91 yuan in the first quarter of 2021, representing a decrease of approximately 76.7%[69]. - Total profit for the first quarter of 2022 was 2,224,783.73 yuan, down from 10,264,645.96 yuan in the same period of 2021, a decrease of approximately 78.3%[68]. Cash Flow - The net cash flow from operating activities for Q1 2022 was approximately ¥672.40 thousand, a decrease of 61.78% compared to the previous year[16]. - Operating cash flow for Q1 2022 was ¥672,398.83, a decrease of 61.9% compared to ¥1,759,329.80 in Q1 2021[73]. - Total cash inflow from operating activities in Q1 2022 was ¥29,758,286.00, down 10.3% from ¥33,388,410.62 in Q1 2021[73]. - Cash and cash equivalents at the end of Q1 2022 totaled ¥56,672,243.01, compared to ¥97,018,175.75 at the end of Q1 2021, reflecting a decrease of 41.5%[74]. - The net increase in cash and cash equivalents for Q1 2022 was ¥24,272,682.04, a decrease of 55.9% from ¥54,958,028.35 in Q1 2021[74]. Assets and Liabilities - The total assets as of March 31, 2022, were approximately ¥276.93 million, a decrease of 0.12% compared to the end of the previous year[16]. - Total liabilities decreased from CNY 13,976,915.25 at the end of 2021 to CNY 12,577,981.62 as of March 31, 2022, a reduction of approximately 10%[61]. - Current liabilities totaled CNY 10,905,745.87, down from CNY 12,452,117.62, reflecting a decrease of about 12.4%[61]. - Shareholders' equity rose to CNY 264,354,416.17 from CNY 263,299,613.77, showing a slight increase of about 0.4%[61]. Investment and Expenses - Investment income in Q1 2022 was 342,800 CNY, a decrease of 658,700 CNY or 65.8% year-on-year[20]. - Research and development expenses decreased to 885,122.06 yuan in the first quarter of 2022 from 1,217,010.58 yuan in the first quarter of 2021, a reduction of approximately 27.3%[68]. - Total operating costs for Q1 2022 amounted to CNY 27,140,635.69, compared to CNY 22,510,138.59 in Q1 2021, indicating an increase of about 20.5%[67]. Shareholder Commitments - Shareholders holding more than 5% of the company's shares have committed to not transfer or manage their shares for twelve months post-listing, with an automatic six-month extension if stock prices fall below the issue price for 20 consecutive trading days[45]. - The lock-up period for shares held by key personnel will automatically extend by six months if the stock price falls below the issue price after six months of listing[46]. - Any income gained from breaching the share transfer commitments will be returned to the company within five days[45]. - The company has established strict fund management systems to prevent any fund occupation incidents[43]. - The commitment to avoid fund occupation will remain effective as long as the actual controller is in position[43]. Compliance and Regulations - The company has committed to a profit distribution policy that aligns with relevant laws and regulations, ensuring compliance post-listing[55]. - The company will disclose any failure to fulfill commitments due to uncontrollable factors in a timely manner[53]. - Any losses incurred by the company or investors due to non-compliance with commitments will result in legal compensation responsibilities for the responsible parties[45]. - The company will take corrective actions within the timeframe required by regulatory authorities if commitments are not fulfilled[54].

Product Development and Innovation - In 2021, the company launched multiple new products, including "Xuebao" and "Xueyang," which enhance blood production and oxygen levels in livestock, contributing to improved feed efficiency [5]. - The product "Xuewang" won the first prize at the 7th China Pig Industry Forum in April 2021, highlighting its market recognition [8]. - The company obtained 5 patents in 2021, showcasing its commitment to innovation and product development [5]. - The company has developed a series of proprietary products aimed at improving feed quality and animal health, including "Blood Oxygen Health" and "Blood Nutrition" series [21]. - The company launched new products including "谷净" and "牲血旺 3 号," which have shown effectiveness in reducing feed costs and improving nutrient utilization in livestock [62][64]. - The company has launched several new products aimed at improving animal health, including alternatives to antibiotics and fishmeal [118]. - The company is focused on research and development to improve feed efficiency and reduce costs, which is critical for the survival of livestock enterprises [61][66]. - The company aims to enhance its research and development in hematopoietic nutrition, focusing on highland dairy cows and aquatic animals to address high mortality rates due to hypoxia [127]. Financial Performance - The company's operating revenue for 2021 was CNY 137,193,196.23, representing a year-on-year increase of 7.73% compared to CNY 127,347,425.82 in 2020 [34]. - The net profit attributable to shareholders for 2021 was CNY 40,017,018.30, showing a slight decrease of 0.17% from CNY 40,083,422.07 in 2020 [34]. - The gross profit margin for 2021 was 43.60%, down from 49.75% in 2020 [34]. - Total assets increased by 30.12% to CNY 277,276,529.02 at the end of 2021, compared to CNY 213,095,119.17 at the beginning of the year [36]. - The total liabilities decreased by 11.51% to CNY 13,976,915.25 at the end of 2021, down from CNY 15,794,988.89 at the beginning of the year [36]. - The net cash flow from operating activities for 2021 was CNY 25,658,464.35, an increase of 5.34% from CNY 24,357,095.17 in 2020 [38]. - The company's weighted average return on equity based on net profit attributable to shareholders was 15.99% in 2021, down from 21.96% in 2020 [34]. - The basic earnings per share for 2021 was CNY 0.25, a decrease of 35.90% compared to CNY 0.39 in 2020 [34]. - The company achieved a revenue of 137.19 million yuan, an increase of 7.73% compared to the same period in 2020, while net profit was 40.02 million yuan, a slight decrease of 0.17% [61]. - The company reported a total of CNY 2.42 million in government subsidies, including CNY 0.3 million for business awards and CNY 1 million for financing subsidies [46]. Market and Industry Challenges - The livestock industry faced challenges in 2021, with a 27.4% increase in pig slaughtering, leading to a significant drop in prices and profitability for farmers [65]. - In 2021, the average price of corn reached 2,442 yuan/ton, an increase of 322 yuan/ton from 2020, contributing to significant cost pressures in the industry [65]. - The company anticipates challenges in 2022 due to low pig prices, which may lead to reduced breeding scales and lower feed demand [137]. - Fluctuations in raw material prices, such as corn, wheat, and soybean meal, may impact the profitability of livestock and feed enterprises [137]. - The company is actively addressing market competition risks from counterfeit products that could harm its brand image and sales [18]. Research and Development - The company is increasing R&D efforts for blood-related products, addressing anemia in susceptible animals as a key industry focus [18]. - The company has established partnerships with renowned universities and research institutions to enhance its R&D capabilities and develop high-value products with independent intellectual property rights [18]. - The company has completed 10 out of 13 R&D projects in 2021, with significant advancements in products aimed at improving livestock health and nutrition [117]. - R&D expenditure for the current period was CNY 3,983,697.54, accounting for 2.91% of operating income, a decrease from 3.70% in the previous period [112]. Corporate Governance and Shareholder Commitments - The company has established a buyback plan to enhance long-term incentive mechanisms and attract talent, reflecting confidence in its future development [148]. - The actual controlling shareholders have provided written commitments to fully compensate for any economic losses arising from lease agreements or potential relocations due to property demolition, with no losses reported during the reporting period [160]. - The company has committed to avoid related party transactions and has established a decision-making system to regulate such transactions, ensuring no related party transactions occurred during the reporting period [158]. - The company has ensured that all employees have paid social insurance, with exceptions for employees from rural areas who voluntarily opted out, and will continue to promote compliance with social insurance regulations [162]. Strategic Growth and Expansion - The company plans to enhance its product offerings by promoting efficient low-protein feed formulations and green feed additives, which are expected to have a broad market outlook during the 14th Five-Year Plan period [70]. - The company plans to establish 100 marketing service outlets nationwide to expand sales channels and improve customer service [129]. - The company plans to expand its production capacity to 9,000 tons annually as part of its growth strategy [190]. - The company is committed to developing cost-reducing and efficiency-enhancing products to support industry growth amid declining pig prices and rising material costs [130]. Awards and Recognition - The company was honored as a "2020 Guangzhou Hidden Champion Enterprise" in September 2021, indicating its competitive position in the industry [9]. - The chairman received multiple awards in 2021, reflecting the leadership's recognition in the agricultural technology sector [9]. - The company received multiple awards, including recognition as a "hidden champion enterprise" in Guangzhou and a first prize in the "China Egg Products Competition" [120].

Group 1: Investor Meeting Overview - The company received 7 institutional investors for a meeting on November 15, 2021 [2] - The meeting was held in the company conference room and included representatives from various investment firms [2] Group 2: Product Highlights - The raw materials used in the company's products comply with the "Feed Raw Material Directory (2018)" and "Feed Additive Variety Directory (2013)" [3] - The company's blood products can effectively improve anemia symptoms in animals, enhancing immunity and meat quality [4] - Products help reduce the need for antibiotics, ensuring the safety of animal meat [4] Group 3: Business Growth Plans - The company aims to serve existing customers better and increase product usage [5] - New product "Gu Jing" can degrade mycotoxins in grain feed with a degradation rate exceeding 90%, at a lower cost than imported alternatives [5] - Plans to expand product development and market outreach in aquaculture, ruminants, and poultry [5]

Group 1: Investor Meeting Overview - The company received 7 institutional investors for research from July 28 to July 31, 2021 [3] - The meeting included on-site communication and visits [3] - Participating institutions included Anxin Securities, Power Capital, Ping An Insurance, Tianhui Investment, Industrial Bank, Bank of Communications, and Guoyuan Securities [3] Group 2: Key Issues Discussed Issue 1: Product Recognition - Intensive farming leads to anemia in animals due to lack of chlorophyll, exercise, minerals, and sunlight [4] - The company has focused on research and production of blood-boosting products, proving their effectiveness and safety through customer trials [4] - The products help improve animal health, reduce feed-to-meat ratio, enhance immunity, and decrease antibiotic use, thus increasing farmers' profits [4] Issue 2: Market Share Improvement - The company is actively recruiting industry talent [5] - It aims to expand product development and market outreach in aquaculture, ruminants, and poultry [5] - The company is working to raise awareness among livestock professionals about anemia and its impacts [5] Issue 3: Future Capital Operations - The company currently has no planned capital operations and will focus on performance improvement [6] - Any future plans will be disclosed in a timely manner [6]